Therapeutics News

A fixed combination of brinzolamide 1% and brimonidine 0.2% was more effective than brimonidine or brinzolamide alone in lowering intraocular pressure, according to a recent study published in Ophthalmology.

Utilization of brimonidine in a seated position significantly lowered intraocular pressure by increasing uveoscleral outflow, according to a recent study published in the Journal of Glaucoma.

Drug-eluting contact lenses have been discussed as a potential treatment modality for decades but have yet to reach patients. To those researching and developing this novel drug delivery method, the lenses continue to represent a possibility of more efficient treatment for a multitude of ocular issues.

When treating patients with glaucoma, optometrists can face many decisions on the way to achieving target intraocular pressure; among these is whether a fixed-combination agent is necessary and, if so, which one to choose.

Each month, ophthalmic journals report new developments from around the world as researchers search for more effective methods of managing patients with or at risk for glaucoma.

In a recent Ophthalmology study, researchers found an association between vasodilator use and early age-related macular degeneration.

Shire plans to submit a New Drug Application to the U.S. Food and Drug Administration for lifitegrast in first-quarter 2015, according to a recent company press release.

NovaBay Pharmaceuticals Inc. announced it has completed patient enrollment in its global phase 2b trial, BAYnovation, testing its solution to treat adenoviral conjunctivitis.

Researchers reported in a recent Retina study that treating diabetic macular edema with ranibizumab is safe when used as needed on certain patients.

In evaluating timolol 0.1% gel compared to timolol 0.5% eye drops, researchers found that both treatments were effective after phacoemulsification surgery.